Oral medicine for 24 hours might block the new coronavirus
- Autoimmunity in Cancer: Mechanisms Implications and the Role in Tumor Immunotherapy
- Moderna to Cut $1.1 Billion in R&D Spending: Halts 5 Projects by 2027
- Fluoride Care Proves Effective in Preventing Cavities in the Elderly
- Positive Results from GSK Phase 2 Clinical Trial of Seasonal Influenza mRNA Vaccine
- High Lead Levels Found in AliExpress Body Paints: Exceeding 92.8 Times
- Injecting Immune Cells Can Significantly Enhance the Healing of Bones Muscles and Skin
Oral medicine for 24 hours might block the new coronavirus
Oral medicine for 24 hours might block the new coronavirus.
The experimental oral drug Molnupiravir of the US pharmaceutical company Merck & Co. (MSD) has recently achieved amazing experimental results.
Studies have confirmed that this antiviral drug can stop the growth of the new coronavirus within 24 hours, thereby inhibiting the spread of the virus.
MSD pharmaceutical companies have started clinical trials in humans, but the results are not expected to be officially released until May 2021.
According to the “Daily Mail” report, after the researchers treated three ferrets infected with the new coronavirus, two uninfected ferrets and one sick ferret were kept in the same cage. After 8 days of testing, the researchers found that the unaffected ferrets kept in the cage were all in peace, but the diseased ferrets who were fed only a placebo were infected with the COVID-19 virus within 4 days Give it to the other ferrets in the same cage.
Professor Richard Plemper of the Institute of Biomedical Research at Georgia State University (GSU) pointed out that the study published in Nature Microbiology proved for the first time that oral medications can quickly block the spread of the new coronavirus.
The US research team used MSD’s experimental oral drug Molnupiravir on ferrets infected with the COVID-19 virus and found that the drug can effectively inhibit the spread of the virus.
The research team believes that if Molnupiravir can achieve similar effects in human trials, then patients with COVID-19s treated with Molnupiravir can become non-infectious within a day. MSD pharmaceutical companies have started clinical trials in humans, but the results are not expected to be officially released until May 2021.
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
